´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2020 the 30th KGOG Symposium and Workshop : 2020-08-15±³À°ÀÏÀÚ : 2020-08-15
±³À°Àå¼Ò : ½¦¶óÅ漿ﰳ²È£ÅÚ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
2020 the 30th KGOG Symposium and Workshop ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-540
À̸ÞÀÏ :
koreagyonco@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 08:10~09:00 Disease site subcommittee workshop-Cervix-vulvar TSC ±è´ë¿¬, ±è¹®È«(¼¿ï¾Æ»êº´¿ø, ¿øÀڷº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 09:00~09:30 Rare tumor subcommittee, DDT subcommittee _ overview Á¤ÇöÈÆ, ±è±âµ¿(¼¿ï´ëº´¿ø, ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 09:30~10:10 Future treatment strategy based on VEGF inhibitor in Frontline Ovarian Cancer: for the new normal through cancer immunotherapy ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 10:30~11:10 Virtual-The recent status and experience of the international and USA clinical trial collaboration Robert Mannel(GOG, USA)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:10~11:30 Virtual-Update of establishing the clinical trial network in East-asian area based on the experience between KGOG and JGOG Takayuki Enomoto(JGOG, Japan)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:30~11:50 Virtual-Overview of clinical trial of cervical cancer in CGCS (China) Xiaohua Wu(CGCS, China)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:50~12:10 Virtual-Experience of clinical trial of GYN Cancer in TGOG Kung-Liahng Wang(TGOG, Taiwan)
Åä·Ð 08¿ù 15ÀÏ ±×·£µåº¼·ë 12:10~12:20 Discussion ()
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 12:20~12:50 Management of chemotherapy induced neutropenia and the role of long-acting G-CSF À¯ÇåÁ¾(Ãæ³²´ëº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 13:30~13:50 Current trends in immuno-oncology on endometrial cancer treatment Kevin Chueh(MSD, A-P)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 14:00~14:50 Disease site subcommittee workshop-Uterine corpus TSC Àå¼®ÁØ, À̱¤¹ü(¾ÆÁִ뺴¿ø, ±æº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 14:50~15:10 Second-line maintenance of ovarian cancer À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 15:10~15:30 First-line maintenance therapy with newly diagnosed advanced ovarian cancer ¾î°æÁø(¿ëÀμ¼ºê¶õ½ºº´¿ø)
Åä·Ð 08¿ù 15ÀÏ ±×·£µåº¼·ë 15:30~15:40 Discussion ()
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 16:00~16:50 Disease site subcommittee worhshop-ovary tsc °¼®¹ü, ÀÌÁ¤¿ø(±¹¸³¾Ï¼¾ÅÍ, »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 16:50~17:40 Niraparib in patients with newly diagnosed advanced ovarian cancer: PRIMA ±è´ë¿¬(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 17:40~18:00 Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer: NOVAPARPi monotherapy for late-line treatment of ovarian cancer ±è»ó¿î(¼¼ºê¶õ½ºº´¿ø)